Figure 3.
Heatmap displaying the relative abundances (log10 transformed) of lolitrem B biotransformation products distributed in the body: (a) kidney (b) liver and brain tissue: (c) cerebral cortex (d) thalamus (e) cerebellum (f) brainstem of mice exposed to lolitrem B at high dose (HD) (2.0 mg/kg b.wt) and low dose (LD) (0.5 mg/kg b.wt) at time points 6 h and 24 h post treatment.
